BioSpace News Archive

Policy

Biopharma Update on the Novel Coronavirus: September 16

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.

September 16, 2020
·
3 min read
·
BioSpace Editorial Staff
Biotech Bay

Hexagon Bio to Move into Clinic with $47 Million in Series A Financing

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.

September 16, 2020
·
2 min read
·
Heather McKenzie
BioCapital

UPMC Researchers Isolate Tiny Antibody That Neutralizes SARS-CoV-2 Virus

The researchers used this antibody, which is 10-times smaller than a full-sized antibody and the smallest isolated biological molecule to date, to develop a potential therapeutic and prophylactic agent against the virus termed “Ab8.”

September 16, 2020
·
2 min read
·
Brandon May
BioSpace Global Roundup, Sept. 17

Companies from across the globe provide updates on their businesses and pipelines.

September 16, 2020
·
5 min read
·
Alex Keown
Career Advice

Driving Industry-Academia Collaboration with a Translational Research Expert

Are you interested in the practical application of life sciences research? If so, an understanding of translational research is useful to see the vast opportunities to help patients and cure diseases.

September 16, 2020
·
6 min read
·
Porschia Parker-Griffin
Policy

NIH Raises Concerns About Potential Safety Issues Associated with AstraZeneca Vaccine

The National Institutes of Health is raising concern about the safety of AstraZeneca’s coronavirus vaccine, even as the U.S. FDA is weighing whether or not to resume testing in the United States following a global pause in the trial for safety reasons.

September 16, 2020
·
3 min read
·
Alex Keown
Policy

Prepping for COVID-19’s Next Wave: Is the Glass Half Full or Half Empty?

With both autumn and flu season fast approaching, nearly everyone is wondering whether we will endure another round of illnesses that will rival that of last spring.

September 16, 2020
·
4 min read
·
Gail Dutton
Business

Unity Bio Cuts 30% of Staff, Restructures to Focus on Ophthalmology and Neurology

UNITY Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology. As part of the plan, it is decreasing its workforce by about 30% to optimize capital.

September 16, 2020
·
3 min read
·
Mark Terry
Drug Development

Eli Lilly’s Antibody Therapy Against COVID-19 Reduced Hospitalization Rates

Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19.

September 16, 2020
·
3 min read
·
Mark Terry
Biotech Bay

Gene Editing Company Graphite Bio Launches with $45 Million in Funding

The company was backed by Versant Ventures, which supported the launch of CRISPR Therapeutics.

September 16, 2020
·
2 min read
·
Alex Keown